Eton Pharmaceuticals, Inc. (ETON): Operating Income
-$844.0K
Year ended 2025-12-31
$16.31M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$844.0K | n/m | 2026-03-19, From 2025-01-01 |
| 2024-12-31 | -$2.60M | n/m | 2026-03-19, From 2024-01-01 |
| 2023-12-31 | -$1.19M | n/m | 2026-03-19, From 2023-01-01 |
| 2022-12-31 | -$8.26M | n/m | 2025-03-18, From 2022-01-01 |
| 2021-12-31 | -$1.50M | n/m | 2024-03-14, From 2021-01-01 |
| 2020-12-31 | -$27.11M | n/m | 2023-03-16, From 2020-01-01 |
| 2019-12-31 | -$18.60M | n/m | 2022-03-16, From 2019-01-01 |
| 2018-12-31 | -$10.32M | n/a | 2021-03-16, From 2018-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | -$844.0K | n/m |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | -$121.50M | n/m |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | -$76.26M | n/m |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | -$22.36M | n/m |
| Nurix Therapeutics, Inc. (NRIX) | 2025-11-30 | -$285.67M | n/m |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | -$179.45M | n/m |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | -$217.10M | n/m |
| Standard Biotools Inc. (LAB) | 2025-12-31 | -$110.25M | n/m |
| Cytokinetics Inc (CYTK) | 2025-12-31 | -$612.26M | n/m |
Compare ETON, ADCT, ARCT, CTMX side by side · Screen every company in Pharmaceutical Preparations ↗